Evidence map›Paper›PMID 33244054›Full record

ArticleScientific reports2020

An efficient machine learning-based approach for screening individuals at risk of hereditary haemochromatosis.

Patricia Martins Conde, Thomas Sauter, Thanh-Phuong Nguyen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Patricia Martins CondeMegeno S.A, Esch-sur-Alzette, Luxembourg.
Thomas SauterUniversity of Luxembourg, Esch-sur-Alzette, Luxembourg.
Thanh-Phuong NguyenMegeno S.A, Esch-sur-Alzette, Luxembourg. phuong.nguyen@megeno.com.
University of Luxembourg · LU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary haemochromatosis (HH) is an autosomal recessive disease, where HFE C282Y homozygosity accounts for 80-85% of clinical cases among the Caucasian population. HH is characterised by the accumulation of iron, which, if untreated, can lead to the development of liver cirrhosis and liver cancer. Since iron overload is preventable and treatable if diagnosed early, high-risk individuals can be identified through effective screening employing artificial intelligence-based approaches. However, such tools expose novel challenges associated with the handling and integration of large heterogeneous datasets. We have developed an efficient computational model to screen individuals for HH using the family study data of the Hemochromatosis and Iron Overload Screening (HEIRS) cohort. This dataset, consisting of 254 cases and 701 controls, contains variables extracted from questionnaires and laboratory blood tests. The final model was trained on an extreme gradient boosting classifier using the most relevant risk factors: HFE C282Y homozygosity, age, mean corpuscular volume, iron level, serum ferritin level, transferrin saturation, and unsaturated iron-binding capacity. Hyperparameter optimisation was carried out with multiple runs, resulting in 0.94 ± 0.02 area under the receiving operating characteristic curve (AUCROC) for tenfold stratified cross-validation, demonstrating its outperformance when compared to the iron overload screening (IRON) tool.

Indexed as

AdultArtificial IntelligenceCohort StudiesFemaleHemochromatosisHemochromatosis ProteinHomozygoteHumansIronIron OverloadMachine LearningMaleMass ScreeningMiddle AgedYoung AdultHemochromatosis ProteinIron

Identifiers

PMID33244054
PMCPMC7691515
OpenAlexW3109298338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.